Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 1005-1011 , November 2006

The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro

  • Erik Samén

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • ,
  • Jan-Olov Thorell

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • ,
  • Anna Fredriksson

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • ,
  • Sharon Stone-Elander

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • Department Clinical Neurosciences, Karolinska Institutet, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • Corresponding Author InformationCorresponding author. Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden. Tel.: +46 8 51775331; fax: +46 8 307346.

Received 7 September 2006 ,Accepted 28 September 2006.

References 

  1. Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer. 2005;12:S17–S27
  2. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9–S15
  3. Fry DW. Mechanism of action of erbB tyrosine kinase inhibitors. Exp Cell Res. 2003;284:131–139
  4. Mulholland GK, Winkle W, Mock BH, Sledge G. Radioiodinated epidermal growth factor receptor ligands as tumor probes. Dramatic potentiation of binding to MDA-468 cancer cells in presence of EGF. J Nucl Med. 1995;36:P71
  5. Johnström P, Fredriksson A, Thorell JO, Stone-Elander S. Synthesis of [methoxy-11C]PD153035, a selective EGF receptor tyrosine kinase inhibitor. J Labelled Compd Radiopharm. 1998;41:623–629
  6. Mulholland GK, Zheng QH, Winkle WL, Carlson KA. Synthesis and biodistribution of new C-11 and F-18 labeled epidermal growth factor receptor ligands. J Nucl Med. 1997;38:P141
  7. Fredriksson A, Johnström P, Thorell JO, von Heijne G, Hassan M, Eksborg S, et al. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci. 1999;65:165–174
  8. Lim JK, Riese DJ, Negash K, Hawkins RA, VanBrocklin HF. Synthesis and in vitro evaluation of epidermal growth factor receptor tyrosine kinase inhibitors. J Nucl Med. 1998;39(Suppl):20P–21P
  9. Lim JK, Riese DJ, VanBrocklin HF. Synthesis of 4-(4(-[18F]fluorobenzylamino)-6,7-diethoxyquinazoline: a positron emitting radioprobe for the epidermal growth factor receptor. J Labelled Compd Radiopharm. 1999;42:S693–S695
  10. Lim JK, Negash K, Hanrahan SM, VanBrocklin HF. Synthesis of 4-(3′-[125I]iodoanilino)-6,7-dialkoxyquinazolines: radiolabeled epidermal growth factor receptor tyrosine kinase inhibitors. J Labelled Compd Radiopharm. 2000;43:1183–1191
  11. Wang JQ, Gao M, Miller KD, Sledge GW, Zheng QH. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett. 2006;16:4102–4106
  12. Bonasera TA, Ortu G, Rozen Y, Krais R, Freedman NM, Chisin R, et al. Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol. 2001;28:359–374
  13. Ben-David I, Rozen Y, Ortu G, Mishani E. Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride. Appl Radiat Isot. 2003;58:209–217
  14. Ortu G, Ben-David I, Rozen Y, Freedman NMT, Chisin R, Levitzki A, et al. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Int J Cancer. 2002;101:360–370
  15. Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A, et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem. 2004;12:3421–3429
  16. Mishani E, Abourbeh G, Rozen Y, Jacobson O, Laky D, Ben I, et al. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol. 2004;31:469–476
  17. VanBrocklin HF, Lim JK, Coffing SL, Hom DL, Negash K, Ono MY, et al. Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J Med Chem. 2005;48:7445–7456
  18. Vasdev N, Dorff PN, Gibbs AR, Nandanan E, Reid LM, O'Neill JP, et al. Synthesis of 6-acrylamido-4-(2-[18F]fluoroanilino)quinazoline: a prospective irreversible EGFR binding probe. J Labelled Compd Radiopharm. 2005;48:109–115
  19. Mishani E, Abourbeh G, Jacobson O, Dissoki S, Ben Daniel R, Rozen Y, et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem. 2005;48:5337–5348
  20. Dissoki S, Laky D, Mishani E. Fluorine-18 labeling of ML04 — presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer. J Labelled Compd Radiopharm. 2006;49:533–543
  21. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000;27:661–670
  22. Meyer JH, Ichise M. Modeling of receptor ligand data in PET and SPECT imaging: a review of major approaches. J Neuroimag. 2001;11:30–39
  23. Eckelman WC. The application of receptor theory to receptor-binding and enzyme-binding oncologic radiopharmaceuticals. Nucl Med Biol. 1994;21:759–769
  24. Eckelman WC. Sensitivity of new radiopharmaceuticals. Nucl Med Biol. 1998;25:169–173
  25. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994;265:1093–1095
  26. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997;3:2099–2106
  27. Kunkel MW, Hook KE, Howard CT, Przybranowski S, Roberts BJ, Elliott WL, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13:295–302
  28. Lee SY, Choe YS, Kim DH, Park BN, Kim SE, Choi Y, et al. A simple and efficient in vitro method for metabolism studies of radiotracers. Nucl Med Biol. 2001;28:391–395
  29. Rewcastle GW, Denny WA, Bridges AJ, Zhou H, Cody DR, McMichael A, et al. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem. 1995;38:3482–3487
  30. Pandey A, Volkots DL, Seroogy JM, Rose JW, Yu JC, Lambing JL, et al. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem. 2002;45:3772–3793
  31. Fredriksson A, Stone-Elander S. Rapid microwave-assisted cleavage of methyl phenyl ethers: new method for synthesizing desmethyl precursors and for removing protecting groups. J Labelled Compd Radiopharm. 2002;45:529–538
  32. Beedham C. The role of non-P450 enzymes in drug oxidation. Pharm World Sci. 1997;19:255–263
  33. Peiris DM, Lam W, Michael S, Ramanathan R. Distinguishing N-oxide and hydroxyl compounds: impact of heated capillary/heated ion transfer tube in inducing atmospheric pressure ionization source decompositions. J Mass Spectrom. 2004;39:600–606
  34. Tong W, Chowdhury SK, Chen JC, Zhong R, Alton KB, Patrick JE. Fragmentation of N-oxides (deoxygenation) in atmospheric pressure ionization: investigation of the activation process. Rapid Commun Mass Spectrom. 2001;15:2085–2090
  35. Bickel MH. The pharmacology and biochemistry of N-oxides. Pharmacol Rev. 1969;21:325–355
  36. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology. 1995;104:1–8
  37. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos. 2002;30:1311–1319
  38. Tracy TS, Marra C, Wrighton SA, Gonzales FJ, Korzekwa KR. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52:293–298
  39. Uckun FM, Thoen J, Chen H, Sudbeck E, Mao C, Malaviya R, et al. CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation. Drug Metab Dispos. 2002;30:74–85
  40. McKillop D, McCormick AD, Miles GS, Phillips PJ, Pickup KJ, Bushby N, et al. In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica. 2004;34:983–1000
  41. McKillop D, Hutchison M, Partridge EA, Bushby N, Cooper CM, Clarkson-Jones JA, et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica. 2004;34:917–934

PII: S0969-8051(06)00195-8

doi: 10.1016/j.nucmedbio.2006.09.008

Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 1005-1011 , November 2006

Article Tools

* Image Usage & Resolution